Goldenwell Biotech, Inc. Liquidation Value

GWLL Food Products

Cash & Equivalents

$45,622
As of 2025-09-30
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $45,622
Total Obligations: -$39,360
$6,262
Per share: $0.00
Period: 2025-09-30
incomplete 3 components missing — treated as $0 in formula. Why?
  • Finance Lease Liability: not reported in this period (annual-only)
  • Long-Term Debt: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $45,622
AR: N/A
Total Obligations: -$39,360
$6,262
Per share: $0.00
Period: 2025-09-30
incomplete 4 components missing — treated as $0 in formula. Why?
  • Accounts Receivable: not reported in this period (annual-only)
  • Finance Lease Liability: not reported in this period (annual-only)
  • Long-Term Debt: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $45,622
AR: N/A
Inventory: $174,788
Total Obligations: -$39,360
$181,050
Per share: $0.00
Period: 2025-09-30
incomplete 4 components missing — treated as $0 in formula. Why?
  • Accounts Receivable: not reported in this period (annual-only)
  • Finance Lease Liability: not reported in this period (annual-only)
  • Long-Term Debt: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$6,262$0.00
Liquid Liquidation Value$6,262$0.00
Operating Liquidation Value$181,050$0.00

Key Components (as of 2025-09-30)

Data as of 2025-09-30 from 10-Q filed 2025-12-08. View on SEC EDGAR →

Cash & Equivalents$45,622
Accounts ReceivableN/A
Inventory$174,788
Current Liabilities$39,360
Long-term DebtN/A
Op. Lease LiabilityN/A
Finance LeaseN/A
Shares Outstanding99.0M

Explore all 48 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2025-09-30$45,622N/A$174,788$0$39,360N/AN/AN/A
2025-06-30$76,507N/A$174,788$0$64,360N/AN/AN/A
2025-03-31$17,127N/A$174,788N/AN/A$176,085N/AN/A
2024-12-31$49,404N/A$174,788$0$1,860$173,985N/AN/A
2024-09-30$4,755N/A$174,677$0N/AN/AN/AN/A
2024-06-30$25,720N/A$174,677$0N/AN/AN/AN/A
2024-03-31$48,442N/A$174,746$0N/AN/AN/AN/A
2023-12-31$53,231N/A$174,863$0N/A$46,335N/AN/A

Comments

SEC Filings

PeriodFormFiledLink
2025-09-30 10-Q 2025-12-08 View
2025-06-30 10-Q 2025-09-12 View
2025-03-31 10-Q 2025-05-27 View
2024-12-31 10-K 2025-05-15 View
2024-09-30 10-Q 2024-11-26 View
2024-06-30 10-Q 2024-08-22 View
2024-03-31 10-Q 2024-05-20 View
2023-12-31 10-K 2024-04-12 View

AI Insights

AI Insight·Generated 2026-05-06

Goldenwell Biotech, Inc. (GWLL) presents a deeply negative liquidation recovery posture as of September 30, 2025. Total assets of $220,410 consist entirely of cash ($45,622) and inventory ($174,788); no PP&E, no intangibles, no receivables. Applying standard liquidation haircuts yields approximately $45,622 (cash at 100%) plus roughly $104,873 (inventory at 60%) for total adjusted asset recovery of approximately $150,500. Total liabilities at face value are $315,233, composed of $39,360 in current liabilities (principally $37,500 unearned service revenue and $1,860 unearned sales revenue), $95,588 in a related-party noncurrent loan from the CEO, and $189,250 in other noncurrent liabilities net of a $8,965 unamortized discount (gross face $189,250 used at face for liquidation purposes). Net liquidation recovery to equity is approximately negative $164,700, consistent with the reported GAAP stockholders deficit of $(94,823) which itself understates the liquidation shortfall due to inventory haircut. The MFFAIS-reported CLV/LLV of $6,262 reflects only the current liquid asset slice net of current liabilities, which is directionally consistent but understates the full liability stack. Since the prior filing (June 30, 2025), total liabilities decreased from $350,633 to $315,233, primarily because $37,500 of unearned service revenue recognized as revenue in Q3 reduced the deferred service revenue balance from $62,500 to $37,500, though the balance sheet now shows $37,500 DeferredRevenueCurrent versus $62,500 in the prior period. Cash declined from $76,507 to $45,622 as operating cash burn continued with no new financing. The inventory balance is unchanged at $174,788 since inception of the related-party purchase in 2021, with zero cost of goods sold recorded in the current period, raising staleness concerns for liquidation purposes — the product (Goldenwell DNA Repair) has not meaningfully turned over, and actual distressed realizable value may be well below the 60% standard haircut. The $189,250 gross long-term liability is tagged as OtherLiabilitiesNoncurrent; the filing does not separately disclose the nature or terms of this obligation beyond the CEO-sourced related-party loans totaling $95,588; the residual $93,662 ($189,250 minus $95,588) is not separately explained in XBRL or in the notes. The company has accumulated a deficit of $1,407,226 since inception, generates de minimis revenue ($62,500 service revenue YTD 2025, zero product sales), and carries a full valuation allowance on $295,518 of deferred tax assets. Going concern qualification is in place.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...